References
  1. Yuantao HOU, Lu LIU, Changlin WANG. Advances in immunotherapy of neuroblastoma. Clinical J Pediatric Surg. 2011; 10(4): 290-293. doi: 10.3969/j.issn.1671-6353.2011.04.020
  2. Heczey A, Louis CU. Advances in chimeric antigen receptor immunotherapy for neuroblastoma. Discov Med. 2013; 16(90): 287-294. PMCID: PMC4106238
  3. Seeger RC. Immunology and Immunotherapy of Neuroblastoma. Semin Cancer Biol. 2011; 21(4): 229-237. doi: 10.1016/j.semcancer.2011.09.012.
  4. Pistoia V, Morandi F, Bianchi G, Pezzolo A, Prigione I, Raffaghello L. Immunosuppressive microenvironment in neuroblastoma. Front Oncol. 2013; 3: 167(1-8). doi: 10.3389/fonc.2013.00167.
  5. Tilak T, Sherawat S, Agarwala S, Gupta R, Vishnubhatla S, Bakhshi S. Circulating T-regulatory cells in neuroblastoma: a pilot prospective study. Pediatr Hematol Oncol. 2014; 31(8): 717-722. doi: 10.3109/08880018.2014.886002.
  6. Long AH, Highfill SL, Cui Y, Smith JP, Walker AJ, Ramakrishna S, El-Etriby R, Galli S, Tsokos MG, Orentas RJ, et al. Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol Res. 2016; 4(10): 869-880. doi: 10.1158/2326-6066.CIR-15-0230.
  7. Komohara Y, Takeya M. CAFs and TAMs: maestros of the tumour microenvironment. J Pathol. 2017; 241(3): 313-315. doi: 10.1002/path.4824.
  8. Hashimoto O, Yoshida M, Koma Y, Yanai T, Hasegawa D, Kosaka Y, Nishimura N, Yokozaki H. Collaboration of cancer-associated fibroblasts and tumour-associated macrophages forneuroblastoma development. J Pathol. 2016; 240(2): 211-223. doi: 10.1002/path.4769.
  9. Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA. Neuroblastoma. Nat Rev Dis Primers. 2016; 2: 16078. doi: 10.1038/nrdp.2016.78.
  10. Jales A, Falahati R, Mari E, Stemmy EJ, Shen W, Southammakosane C, Herzog D, Ladisch S, Leitenberg D. Ganglioside-exposed dendritic cells inhibit T-cell effector function by promoting regulatory cell activity. Immunology. 2011; 132(1): 134-143. doi: 10.1111/j.1365-2567.2010.03348.x.
  11. Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol. 2010; 184(6): 3106-3116. doi: 10.4049/jimmunol.0902661.
  12. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ Tcells. J Immunol. 2009; 183(2): 937-944. doi: 10.4049/jimmunol.0804253.
  13. Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell  transfer in breast cancer. Cancer Res. 2014; 74(1): 104-118. doi: 10.1158/0008-5472.CAN-13-1545.
  14. Xu W, Cai J, Li S, Zhang H, Han J, Wen M, Wen J, Gao F. Improving the in vivo persistence, distribution and function of cytotoxic T lymphocytes by inhibiting the tumor immunosuppressive microenvironment. Scand J Immunol. 2013; 78(1): 50-60. doi: 10.1111/sji.12065.
  15. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-08. PMID: 18546601.
  16. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013; 13(6): 397-411. doi: 10.1038/nrc3526.
  17. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinate dregulation of myeloid cells by tumors. Nat Rev Immunol. 2012; 12(4): 253-268. doi: 10.1038/nri3175.
  18. Jordan KR, Kapoor P, Spongberg E, Tobin RP, Gao D, Borges VF, McCarter MD. Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients. Cancer Immunol Immunother. 2017; 66(4): 503-513. doi: 10.1007/s00262-016-1953-z.
  19. Solito S, Pinton L, Mandruzzato S. In Brief: Myeloid-derived suppressor cells in cancer. J Pathol. 2017 Jan 18. [Epub ahead of print]  doi: 10.1002/path.4876.
  20. Gabrilovich DI. Myeloid-Derived suppressor cells. Cancer Immunol Res. 2017; 5(1): 3-8. doi: 10.1158/2326-6066.CIR-16-0297.
  21. Chen J, Ye Y, Liu P, Yu W, Wei F, Li H, Yu J. Suppression of T cells by myeloid-derived suppressor cells in cancer. Hum Immunol. 2017; 78(2): 113-119.  doi: 10.1016/j.humimm.2016.12.001.
  22. Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell. 1994; 76(2): 263-274. PMID: 8293463.
  23. Selleri C, Maciejewski JP, Catalano L, Ricci P, Andretta C, Luciano L, Rotoli B. Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies. Cancer. 2002; 95(9): 1911-1922. doi: 10.1002/cncr.10915
  24. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ Tcells. J Immunol. 2009; 183(2): 937-944. doi: 10.4049/jimmunol.0804253.
  25. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother. 2010; 59(10): 1593-1600. doi: 10.1007/s00262-010-0855-8.
  26. Ku AW, Muhitch JB, Powers CA, Diehl M, Kim M, Fisher DT, Sharda AP, Clements VK, O’Loughlin K, Minderman H, Messmer MN, Ma J, Skitzki JJ, Steeber DA, Walcheck B, Ostrand-Rosenberg S, Abrams SI, Evans SS. Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes. Elife. 2016; 5. pii: e17375. doi: 10.7554/eLife.17375.
  27. Hassin D, Garber OG, Meiraz A, Schiffenbauer YS, Berke G. Cytotoxic T lymphocyte perforin and Fas ligand working in concert even when Fas ligand lytic action is still not detectable. Immunology. 2011; 133(2): 190-196. doi:10.1111/j.1365-2567.2011.03426.x
  28. Kim JH, Kang TH, Noh KH, Bae HC, Kim SH, Yoo YD, Seong SY, Kim TW. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death. Immunol Lett. 2009; 122(1): 58-67. doi:10.1016/j.imlet.2008.12.006
  29. Martínez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res. 2015; 21(22):5047-5056. doi: 10.1158/1078-0432.CCR-15-0685.
  30. Voskoboinik I, Whisstock JC, Trapani JA. Perforin and granzymes: function, dysfunction and human pathology. Nat Rev Immunol. 2015; 15(6): 388-400. doi:10.1038/nri3839
  31. Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ. 2010; 17(4): 616-623. doi:10.1038/cdd.2009.206.
  32. Alizadeh D, Katsanis E, Larmonier N. Chemotherapeutic targeting of myeloid-derived suppressor cells. Oncoimmunology. 2014; 3(1): e27359. PMID: 24653963.
  33. Hsu FT, Chen TC, Chuang HY, Chang YF, Hwang JJ. Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice. Oncotarget. 2015; 6(42): 44134-44150. doi: 10.18632/oncotarget.6628.